This is an edited version of an article written by Ryan Scott and published in OncLive Oct. 12, 2022
Frontline niraparib (Zejula) maintenance sustained a progression-free survival (PFS) benefit in patients with advanced ovarian cancer, according to updated data from the phase 3 PRIMA trial presented at the 2022 ESMO Congress.
Notably, investigators observed a PFS benefit in patients who received niraparib irrespective of homologous recombination–deficient (HRD) status, according to Antonio González-Martín, MD, PhD.
At a median follow-up of 3.5 years, findings showed that patients in the overall population treated with niraparib (n = 484) achieved a median PFS of 13.8 months vs 8.2 months for patients treated with placebo…. Additionally, patients with HRD tumors treated with niraparib (n = 245) experienced a median PFS of 24.5 months vs 11.2 months for those treated with placebo.
“Our data are contributing to the body of evidence that PARP inhibitors are changing the natural history of patients with HRD [ovarian cancer] in the frontline,” González-Martín said. “Our data confirm the sustained benefit of [niraparib] in this setting. This is an alternative as monotherapy for the maintenance of patients with HRD tumors.”